Methaqualone

Methaqualone is a synthetic quinazolinone sedative-hypnotic that achieved significant medical use and notoriety as a recreational drug in the 1960s and 1970s, known culturally by the brand names Quaalude (United States), Mandrax (United Kingdom), and Sopor. It was withdrawn from medical markets and placed on Schedule I in the United States in 1984, but achieved legendary status in American popular culture — referenced in films, music, and literature as a symbol of 1970s excess — that has ensured lasting fascination decades after its disappearance from legal commerce.

Methaqualone produces a distinctive combination of sedation, euphoria, and muscle relaxation through a GABA-A-mediated mechanism distinct from both benzodiazepines and barbiturates, as established by a 2015 pharmacological study. This mechanistic distinction may underlie what users described as a qualitatively unique experience — a characteristic "Quaalude high" combining disinhibition, euphoria, and sensory enhancement with a tactile "warmth" and loss of inhibition that differentiated it from barbiturates and early benzodiazepines in user accounts. Community accounts from those with historical experience frequently describe it as irreplaceable and distinctly different from other depressants.

Contemporary methaqualone is essentially unavailable in pharmaceutical-grade form in Western countries — what circulates on illicit markets is primarily manufactured in illicit laboratories or diverted from regions with continued illicit manufacture. Product quality, purity, and dose accuracy are deeply unreliable. South African illicit Mandrax production represents the largest known contemporary source. The combination of potent GABA-A activity, significant addiction liability, withdrawal seizure risk, and unreliable illicit product quality makes contemporary methaqualone use particularly hazardous compared to its historical pharmaceutical context.